Stifel Begins Coverage of Tango Therapeutics with Bullish Outlook

Stifel initiates coverage of Tango Therapeutics with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035.